Diffuse large B-cell non-Hodgkins lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Tilly, H ^a,c   Dreyling, M ^b,c  

^a CENTRE HENRI BECQUEREL   (France)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

AGE DISTRIBUTION; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RELAPSE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; ELDERLY CARE; FEBRILE NEUTROPENIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TUMOR BIOPSY; PRACTICE GUIDELINE; RECURRENT DISEASE;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING; RECURRENCE;

EID: 45149103555     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn093     Document Type: Article

References (13)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC 2001.
2. Shipp M, Harrington D, Anderson J et al. A predictive model for aggressive non-Hodgkins lymphoma. N Engi J Med 1993; 329: 987-994.
3. Cheson BD, Pfistner B, Juweid ME at al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
4. Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy in localized aggresive lymphoma. N Engl J Med 2005; 352: 1197-1205.
5. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study of the Groupe dEtudes des Lymphomes de lAdulte. J Clin Oncol 2007; 25: 1-6.
7. Pfreundschuh M, Trumper L, Kloess M et al. German High-Grade Non-Hodgkins Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-82 trial of the DSHNHL. Blood 2004; 104: 634-641.
8. Pfreundschuh MG, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma-a randomized controlled trial by the Mab Thera International Trial (MinT) Group. Early stopping after the first interim analysis. Lancet Oncol 2006; 7: 379-391.
9. Plfreundschuh MG, Kloess M, Schmitz R et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-1 4) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2005: 106 (Abstr 13).
10. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkins lymphoma. N Engl J Med 1995; 333: 1540-1545.
11. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as secondline therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B cell lymphoma. Blood 2004; 103: 3684-3688.
12. Khouri IF, Saliba RM, Hosing C et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkins lymphomas. J Clin Oncol 2005; 23: 2240-2247.
13. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-773.